Licensing Vivitrex: A Win for the Mid-sized Pharma and Specialists

Cephalon's acquisition of US rights to Alkermes' Vivitrex, a long-acting formulation of the alcohol abuse drug naltrexone, is a clear sign that mid-sized companies with marketed products can--thanks to their significant cash flows--contend with Big Pharma for important specialist products.

Cephalon Inc. 's acquisition of US rights to Alkermes Inc. 's Vivitrex (long-acting formulation of the alcohol abuse drug naltrexone) is a clear sign that mid-sized companies with marketed products can—thanks to their significant cash flows—contend with Big Pharma for important specialist products [See Deal].

Not only did Cephalon convince Alkermes it could do as good or better a job marketing the product than a...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Leadership

More from In Vivo